Boehringer Details Survodutide Phase 3 SYNCHRONIZE Data

Phase 3 clinical trials evaluated survodutide, a dual-acting glucagon/GLP-1 receptor agonist, for weight management and liver health.

A powerful new dual-acting medication could soon change how patients manage both obesity and liver health. At the June 2026 American Diabetes Association (ADA) Scientific Sessions, Boehringer Ingelheim showcased pivotal Phase 3 results for survodutide. This treatment acts as a glucagon/GLP-1 receptor agonist—a molecule that mimics dual natural hormones to curb appetite while directly boosting liver fat metabolism.

Published in The New England Journal of Medicine and Nature Medicine, findings from the SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials show that this dual approach targets body fat and clears fat from the liver. Patients achieved dramatic overall weight loss along with unprecedented reductions in abdominal fat. However, researchers also observed that a portion of participants discontinued the weekly injections due to common digestive side effects.

How Does Survodutide Work and Differ From Other Weight-Loss Drugs?

Developed by Boehringer Ingelheim and Zealand Pharma, survodutide simultaneously activates both the GLP-1 and glucagon receptors to drive metabolic improvements. This dual action sets it apart from older, single-target medications that patients use today. For example, popular semaglutide treatment programs rely solely on GLP-1 receptor activation to increase fullness and slow down digestion.

Other multi-receptor drugs target different pathways to manage weight and blood sugar. Doctors frequently prescribe tirzepatide options, which stimulate both GLP-1 and GIP receptors. Survodutide, however, introduces glucagon activation into the mix, which specifically signals the liver to burn more energy and break down stored fats.

By combining GLP-1's appetite-suppressing power with glucagon's fat-burning signal, survodutide accelerates metabolic rate. Investigators believe this distinct dual mechanism explains why the medication specifically reduces harmful abdominal and liver fat. This makes it a promising option for patients with metabolic conditions.

What Did the SYNCHRONIZE-1 Trial Reveal About Weight Loss?

The 76-week Phase 3 SYNCHRONIZE-1 trial evaluated the safety and efficacy of survodutide in 725 adults living with obesity or overweight. Participants did not have type 2 diabetes and received weekly injections of either a placebo or survodutide. The trial primary goals focused on overall weight changes and the percentage of patients losing at least 5% of their weight.

Patients receiving survodutide achieved an average weight reduction of up to 16.6% at 76 weeks, compared to just 3.2% in the placebo group. To understand where this weight loss came from, researchers used detailed MRI scans to track body composition changes. The results showed that survodutide treatment led to a 34% relative reduction in deep visceral fat, which is the dangerous fat surrounding vital organs.

Furthermore, patients experienced up to a 63.1% relative reduction in liver fat, while preserving precious muscle. Only 10.8% of the total weight lost came from lean muscle tissue, compared to the 20% to 40% muscle loss typically seen in standard diets. This indicates that survodutide targets harmful fat deposits while keeping patients strong.

Can Survodutide Successfully Treat Liver Disease and MASLD?

The Phase 3 SYNCHRONIZE-MASLD trial evaluated 216 adults living with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), which is a buildup of excess fat in the liver. This progressive disease can lead to severe inflammation, scarring, and permanent liver damage if left untreated. Over 48 weeks, participants received weekly injections of either a 6.0 mg dose of survodutide or a placebo.

The results, published in Nature Medicine, showed that a remarkable 60% of patients treated with survodutide achieved complete normalization of their liver fat content. Researchers defined normalization as reducing liver fat to 5% or less. Additionally, up to 84.2% of patients on survodutide achieved at least a 30% relative reduction in liver fat, compared to only 24.3% in the placebo group.

Because approved options for metabolic liver diseases are highly limited, these outcomes generated significant excitement among clinical experts. The trial suggests that dual glucagon/GLP-1 receptor agonists could play a major role in halting liver disease progression. Researchers hope these benefits will prevent long-term complications like liver scarring and cirrhosis.

What Are the Side Effects and Discontinuation Rates of Survodutide?

Survodutide's safety results align closely with the established side effects of other GLP-1 medications. The most common issues reported in the SYNCHRONIZE trials were digestive, including nausea, vomiting, diarrhea, and constipation. These symptoms occurred most frequently during the initial dose-escalation phase as patients increased their weekly doses.

However, the trials highlighted significant tolerability challenges that patients and doctors should note. Specifically, 19% of patients in the survodutide group stopped taking the medication due to side effects, compared to just 2.9% in the placebo group. Most of these dropouts occurred during the early weeks of treatment when the dose was rising.

Boehringer Ingelheim suggests that slower dose titration and supportive care in clinical practice could reduce these dropouts. Medical experts emphasize that managing these digestive side effects will be key for patients using this medication. Healthcare providers will need to work closely with patients to ensure long-term treatment success.

How Will Survodutide Shape the Future of Metabolic Treatments?

The SYNCHRONIZE trials published in The New England Journal of Medicine and Nature Medicine mark a major advancement in multi-receptor therapies. The findings suggest that targeting both glucagon and GLP-1 can address obesity and liver disease at the same time. The ability to protect muscle mass while burning visceral and liver fat sets survodutide apart from older therapies.

Currently, survodutide is an investigational drug and has not yet received FDA approval for weight management or MASLD. The manufacturer plans to use these Phase 3 results as the foundation for global regulatory submissions. Meanwhile, patients seeking support can consult a doctor to see which current options are available.

You can check if you qualify for existing medical weight loss treatments or view current pricing to explore available options. As clinical trials progress, healthcare providers will continue to evaluate safety and tolerability data to find the best solutions. These emerging therapies represent a hopeful frontier for metabolic and liver health.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.